Press Releases

Press Releases

or

June 11, 2021
The Phase 3 ALPINE trial met the primary endpoint at interim analysis, with BRUKINSA showing superiority in investigator-assessed overall response rate versus ibrutinib Early progression-free survival and overall survival data are supportive of findings in response rate BRUKINSA demonstrated
June 7, 2021
BEIJING, China & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 7, 2021-- BeiGene, Ltd . (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Center for Drug Evaluation (CDE) of the China National
June 1, 2021
BRUKINSA demonstrated superior objective response rate by investigator assessment in the planned interim analysis BRUKINSA was associated with a statistically significant lower risk of atrial fibrillation or flutter Company to host investor call and webcast on Friday, June 11 at noon ET CAMBRIDGE,